Audentes Therapeutics, a preclinical biotech developing gene therapies for rare diseases, announced terms for its IPO on Monday.
The San Francisco, CA-based company plans to raise $75 million by offering 5 million shares at a price range of $14 to $16. Insiders intend to purchase $30 million worth of shares (40%) in the offering. At the midpoint of the proposed range, Audentes Therapeutics would command a fully diluted market value of $341 million.
Audentes Therapeutics was founded in 2012 and plans to list on the Nasdaq under the symbol BOLD. BofA Merrill Lynch, Cowen & Company and Piper Jaffray are the joint bookrunners on the deal. It is expected to price during the week of July 18, 2016.
